NovoCure (NVCR) EBT Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -2.47% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.77% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.70% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 37.81% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 4.82% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 32.11% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 61.06% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -2.57% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 14.40% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -10.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.68% |
| Dec 31, 2025 | -7.95% |
| Sep 30, 2025 | -8.63% |
| Jun 30, 2025 | -14.41% |
| Mar 31, 2025 | -129.23% |
| Dec 31, 2024 | -29.24% |
| Sep 30, 2024 | -27.02% |
| Jun 30, 2024 | -19.75% |
| Mar 31, 2024 | -126.20% |
| Dec 31, 2023 | -85.34% |
| Sep 30, 2023 | -85.36% |
| Jun 30, 2023 | -148.29% |
| Mar 31, 2023 | -106.36% |
| Dec 31, 2022 | -173.47% |
| Sep 30, 2022 | -171.50% |
| Jun 30, 2022 | -715.91% |
| Mar 31, 2022 | 33.34% |
| Dec 31, 2021 | -33.19% |
| Sep 30, 2021 | -11.28% |
| Jun 30, 2021 | -10.00% |
| Mar 31, 2021 | 46.17% |
| Dec 31, 2020 | 48.59% |
| Sep 30, 2020 | 49.88% |
| Jun 30, 2020 | 30.62% |
| Mar 31, 2020 | 28.37% |
| Dec 31, 2019 | -26.54% |
| Sep 30, 2019 | 26.88% |
| Jun 30, 2019 | 89.56% |
| Mar 31, 2019 | 36.07% |
| Dec 31, 2018 | 29.94% |
| Sep 30, 2018 | 32.68% |
| Jun 30, 2018 | 29.25% |
| Mar 31, 2018 | 8.03% |
| Dec 31, 2017 | -29.97% |
| Sep 30, 2017 | 23.39% |